Recent discussions on X about Abbott Laboratories (ABT) have been buzzing with reactions to the company’s latest financial performance and insider trading activity. Many users are focusing on the strong earnings momentum reported in recent quarters, with some expressing optimism about the healthcare giant’s revenue growth and insider confidence. However, there are also notes of caution as a significant stock sale by a top executive has raised eyebrows among investors.
Additionally, posts on X highlight a divergence in opinions regarding the stock’s technical outlook, with some pointing to bullish signals in price charts, while others warn of potential risks tied to market sentiment and insider selling. The conversation remains dynamic, as investors weigh the implications of robust fundamentals against recent corporate moves. This mix of perspectives keeps the dialogue around ABT engaging and multifaceted.
Note: This discussion summary was generated from an AI condensation of post data.
Abbott Laboratories Congressional Stock Trading
Members of Congress have traded $ABT stock 11 times in the past 6 months. Of those trades, 5 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $ABT stock by members of Congress over the last 6 months:
- REPRESENTATIVE THOMAS H. KEAN, JR. purchased up to $15,000 on 07/21.
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 07/18, 03/06.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 06/24 and 1 sale worth up to $15,000 on 07/10.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $100,000 on 05/12.
- REPRESENTATIVE BRUCE WESTERMAN has traded it 2 times. They made 1 purchase worth up to $15,000 on 03/03 and 1 sale worth up to $15,000 on 04/21.
- REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 2 purchases worth up to $30,000 on 03/20 and 0 sales.
- SENATOR SHELLEY MOORE CAPITO sold up to $15,000 on 02/24.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Abbott Laboratories Insider Trading Activity
Abbott Laboratories insiders have traded $ABT stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $ABT stock by insiders over the last 6 months:
- LISA D EARNHARDT (EVP AND GROUP PRESIDENT) has made 0 purchases and 2 sales selling 91,367 shares for an estimated $12,227,296.
- PHILIP P BOUDREAU (EVP AND CFO) sold 5,550 shares for an estimated $746,758
- SALLY E. BLOUNT sold 2,600 shares for an estimated $337,116
- LOUIS H. MORRONE (EXECUTIVE VICE PRESIDENT) sold 1,111 shares for an estimated $153,506
- ANDREA F WAINER (RETIRED EVP) sold 949 shares for an estimated $131,123
- MARY K MORELAND (EXECUTIVE VICE PRESIDENT) sold 791 shares for an estimated $109,292
- JOHN A. JR. MCCOY (VICE PRESIDENT AND CONTROLLER) sold 562 shares for an estimated $77,651
- ERIC SHROFF (Senior Vice President) sold 562 shares for an estimated $77,651
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Abbott Laboratories Hedge Fund Activity
We have seen 1,440 institutional investors add shares of Abbott Laboratories stock to their portfolio, and 1,469 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL RESEARCH GLOBAL INVESTORS removed 8,968,261 shares (-17.7%) from their portfolio in Q2 2025, for an estimated $1,219,773,178
- CAPITAL INTERNATIONAL INVESTORS removed 6,687,339 shares (-10.0%) from their portfolio in Q2 2025, for an estimated $909,544,977
- PRICE T ROWE ASSOCIATES INC /MD/ added 6,178,992 shares (+148.2%) to their portfolio in Q2 2025, for an estimated $840,404,701
- GAMMA INVESTING LLC removed 5,057,001 shares (-99.1%) from their portfolio in Q2 2025, for an estimated $687,802,706
- WELLINGTON MANAGEMENT GROUP LLP removed 4,712,836 shares (-15.8%) from their portfolio in Q2 2025, for an estimated $640,992,824
- BLACKROCK, INC. added 4,309,866 shares (+3.1%) to their portfolio in Q2 2025, for an estimated $586,184,874
- BOSTON PARTNERS removed 3,107,794 shares (-99.0%) from their portfolio in Q2 2025, for an estimated $422,691,061
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Abbott Laboratories Government Contracts
We have seen $122,499,162 of award payments to $ABT over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- VISN 9 CHEMISTRY AUTOMATION COST PER RESULTS REPORTABLE: $8,212,792
- VISN1 BPA FOR IMMUNOCHEMISTRY CPRR TESTING: $4,077,450
- CHEMISTRY IMMUNOASSAY ANALYZER COST PER REPORTABLE RESULT (CPRR): $4,000,483
- CHEMISTRY ANALYZERS COST PER REPORTABLE RESULTS: $3,555,612
- CIVILIAN DRUG FREE WORKPLACE COLLECTIONS AND MEDICAL REVIEW OFFICER SUPPORT SERVICES: $3,179,454
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Abbott Laboratories Analyst Ratings
Wall Street analysts have issued reports on $ABT in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 07/18/2025
- Jefferies issued a "Buy" rating on 07/18/2025
- Raymond James issued a "Outperform" rating on 07/18/2025
- BTIG issued a "Buy" rating on 07/18/2025
- RBC Capital issued a "Outperform" rating on 07/15/2025
- Piper Sandler issued a "Overweight" rating on 04/17/2025
- Barclays issued a "Overweight" rating on 04/17/2025
To track analyst ratings and price targets for Abbott Laboratories, check out Quiver Quantitative's $ABT forecast page.
Abbott Laboratories Price Targets
Multiple analysts have issued price targets for $ABT recently. We have seen 14 analysts offer price targets for $ABT in the last 6 months, with a median target of $145.0.
Here are some recent targets:
- Lawrence Biegelsen from Wells Fargo set a target price of $142.0 on 07/18/2025
- Anthony Petrone from Mizuho set a target price of $135.0 on 07/18/2025
- Jayson Bedford from Raymond James set a target price of $141.0 on 07/18/2025
- Matthew Taylor from Jefferies set a target price of $145.0 on 07/18/2025
- Marie Thibault from BTIG set a target price of $145.0 on 07/18/2025
- David Lewis from Morgan Stanley set a target price of $137.0 on 07/15/2025
- Shagun Singh from RBC Capital set a target price of $147.0 on 07/15/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
